Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Tamoxifen 10 MG — Blinded tamoxifen 10 mg every other day
  • Drug: Exemestane 25 MG — Blinded exemestane 25 mg every other day

Primary Outcomes

  • Quality of life MEnQol (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-01-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Andrea DeCensi
Collaborators: Dana-Farber/Brigham and Women's Cancer Center, Herbert Irving Comprehensive Cancer Center, Istituto Europeo di Oncologia, Breast Cancer Research Foundation
Principal Investigators:
  • Andrea U De Censi, MD (STUDY_CHAIR) - Ente Ospedaliero Ospedali Galliera
Contact Information
Study Contact:
Andrea U De Censi, MD
+39.010.563.4501
andrea.decensi@galliera.it
Davide S Corradengo, SC
+39.010.563.4580
davide.corradengo@galliera.it
Andrea De Censi, MD
+390105634501
andrea.decensi@galliera.it
E.O. Ospedali Galliera
Interventions
  • Drug: Tamoxifen 10 MG — Blinded tamoxifen 10 mg every other day
  • Drug: Exemestane 25 MG — Blinded exemestane 25 mg every other day
Study Locations (1 sites)
E.O. Ospedali Galliera, Genova, Italy 16128 Italy
Eligibility Criteria
Inclusion Criteria: 1. Postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post- menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Any of the following criteria must be met: 1. Recent (within 12 months from date of consent form signature) histologic diagnosis of ER+ve (\>5%) DCIS (patients with DCIS should have undergone breast-conserving therapy i.e. lumpectomy to remove the tumor with negative surgical margins followed by radiotherapy) or diagnosis within 3 years of HRL (ADH, LCIS, ALH), or: 2. At least 3% breast cancer risk at 5 years (or 5% risk at 10yrs) per one of the following risk models: the Breast Cancer Surveillance Consortium risk calculator V3 or Tyrer-Cuzick model V8 or: 3. Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM), or women with chest wall irradiation before age of 30 years. 2. Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) 0-1. 3. Able to swallow oral medications. 4. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Specifically, all cancers diagnosed since 3 years or longer except for breast and endometrial are eligible. 5. Ability to understand and the willingness to sign a written informed consent document. 6. Mammography performed up to 6 months before the trial consent form signature. 7. DEXA performed up to 12 months before the trial consent form signature. 8. Patients with life expectancy ≥ 10 years. 9. Patients with normal liver function tests and blood cell count. 10. Negative gynaecological examination performed up to 6 months before the trial consent form signature. Exclusion Criteria: 1. Pre/perimenopausal women 2. History of DVT or PE. 3. Endometrial cancer. 4. Macular disorders. 5. Inability to comply with study procedures. 6. Prior use of antiestrogens within 12 months from the date of the trial consent form signature. 7. Use of hormone replacement therapy (HRT) within 3 months from the date of the trial consent form signature. 8. Severe osteoporosis (T score ≤ 2.5 at either spine or hip), or recent vertebral fracture (within 6 months) not treated with zolendronic acid or denosumab. 9. Use of terbinafine, quinidine, cinacalcet, rifampicin, phenytonin, carbamazepine, phenobarbital, and St. John's wort, warfarin, erythromycin, cyclosporin, nifepidine and any concomitant coumarin-type anticoagulant therapy. 10. Patients with moderate or severe renal impairment. 11. Patients with a known hypersensitivity to study drugs.
Conditions Women's Health: Neoplasm of Breast
Phase NA
Enrollment 10000
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity\>75% and specificity\>90% in breast cancer (BC) detection on 10.000 volunteers undergoing regular screening programs.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: MammoWave — Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study. A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts. The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave. When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm.

Primary Outcomes

  • MammoWave® sensitivity (During the procedure)
  • MammoWave® specificity (During the procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-15
Completion: 2026-12-15
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Umbria Bioengineering Technologies
Collaborators: London South Bank University, ELAROS 24/7 Limited (UK), Servicio De Salud De Castilla La Mancha (Spain), IMT School for Advanced Studies Lucca, EVITA - Cancro Hereditário (Portugal), Fondazione Toscana Life Sciences (Italy)
Contact Information
Study Contact:
Gianluigi Tiberi
0039 3490564302
gianluigi@ubt-tech.com
Sabatino Tiberi
s.tiberi@ubt-tech.com
Massimo Calabrese
massimo.calabrese@hsanmartino.it
IRCCS Policlinico San Martino
Interventions
  • Device: MammoWave — Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study. A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts. The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave. When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm.
Study Locations (10 sites)
IRCCS Policlinico San Martino, Genova, Genova 16132 Italy
Ospedale San Giovanni Battista - USL Umbria 2, Foligno, Perugia 06034 Italy
Az. San. Univ. Giuliano Isontina (ASU GI), Trieste, 34128 Italy
Pomeranian Medical University Hospital, Szczecin, Poland
Champalimaud Foundation, Lisbon, Portugal
Clínica Dr. Passos Ângelo in Lisbon, Lisbon, Portugal
Hospital Universitario Reina Sofía- Córdoba, Córdoba, Spain
Hospital General Universitario Morales Meseguer, Murcia, Spain
Complejo Hospitalario Universitario de Toledo, Toledo, Spain
Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: * Women aged between 45 and 74 years * Asymptomatic * Signed informed consent form before starting any study activity * Average risk of BC (every woman except those with know BRCA1, 2, TP53, and/or previous BC) * Mammographic test, either 2D FFDM or 3D Digital Breast Tomosynthesis (DBT) (collecting oblique mediolateral projection \[MLO\] of the right breast, craniocaudal projection \[CC\] of the right breast, MLO projection of the left breast, CC projection of the left breast), performed within the past month with available results or planned to be performed in the same day of the MammoWave test or in the subsequent days * Spontaneous willingness to comply with CIP and recommendations Exclusion Criteria: * Woman with breast prostheses * Women with symptoms or some sign of suspected BC * Women with BRCA1, 2, TP53 or previous BC * Pregnant women * Women who do not have mammographic manifestation of the tumor (known occult breast tumor with only axillar manifestation) * Women with breast size larger than the largest MammoWave cup size
Conditions Hypertension
Phase NA
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study, OBPM\_Calfree2024, with N = 85 participants minimum over 1 visit (lasting around 1h), has been designed to collect raw optical data with Aktiia.product-G2C Clinical investigational system together with several reference systems within a cohort of subjects characterized by a wide variety of phenotypes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Investigational device Aktiia G2C — Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
  • Device: Marketed device used as reference for blood pressure monitoring: double auscultation cuff — Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2 — Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff — Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff — Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
  • Device: Marketed device used as reference for pulse rate monitoring: pulse finger oximeter — Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.

Primary Outcomes

  • Number of study subjects that contribute with analyzable raw data collected (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-25
Completion: 2025-12-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aktiia SA
Contact Information
Study Contact:
Grégoire Wuerzner, Medical Doctor Prof.
+41213140223
gregoire.wuerzner@chuv.ch
Grégoire Wuerzner, MD Prof
+41213141131
gregoire.wuerzner@chuv.ch
CHUV
Interventions
  • Device: Investigational device Aktiia G2C — Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
  • Device: Marketed device used as reference for blood pressure monitoring: double auscultation cuff — Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2 — Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff — Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
  • Device: Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff — Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
Study Locations (1 sites)
CHUV, Lausanne, 1011 Switzerland
Eligibility Criteria
Inclusion Criteria: * Subjects aged 21 to 85yo * Subjects fluent in written and spoken French * Subjects agreeing to attend the study visit and follow study procedures * Subjects that have signed the informed consent form. Exclusion Criteria: * Amputated index fingers * Damaged/injured skin at index fingers * Damaged/injured skin at wrists * Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including tachycardia (heart rate at rest \> 120bpm) and atrial fibrillation * Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR \< 30mL/min/1.73 m2), hyper-/hypothyroidism, pheochromocytoma or arteriovenous fistula * Pregnant women * Polyneuropathy

7T Amygdala and Citalopram Study

NCT06412315
Recruiting
Conditions Emotional Processing, Cognition, Mood Di...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: Citalopram — Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
  • Drug: Placebo — Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once

Primary Outcomes

  • Neural measures: fMRI BOLD univariate analysis (3 hours after dosing for approximately 1 hour)
  • Neural measures: fMRI BOLD multivariate analysis (3 hours after dosing for approximately 1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-13
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oxford
Contact Information
Study Contact:
Marieke AG Martens, DPhil
+441865 618338
marieke.martens@psych.ox.ac.uk
Catherine J Harmer, DPhil
+441865 618326
catherine.harmer@psych.ox.ac.uk
Interventions
  • Drug: Citalopram — Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
  • Drug: Placebo — Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Study Locations (1 sites)
University of Oxford, Department of Psychiatry, Oxford, Oxfordshire OX37JX United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the research * Sufficiently fluent English to understand and complete the task Exclusion Criteria: * Participants with ferromagnetic objects in their bodies (e.g. metal implants, vessel clips, shrapnel injuries) or with implanted devices which may be damaged by the magnet (e.g. heart pacemakers) * Any other MRI contraindication following MRI safety screening * History or current significant psychiatric illness (like major depressive disorder) * Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report * Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the opinion of the study medic would affect the scientific integrity of the study * Currently or within last 3 months taking psychoactive medications (requires further discussion with researcher) * Current or within the last 3 months use of medication that might interact with the effects of citalopram or affect the scientific integrity of the study * Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, previous diagnosis of angle-closure glaucoma, or current use of any other medication whose use interacts with citalopram (according to British National Formulary (BNF) guidance) e.g. associated with prolonged QT-interval * Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study including epilepsy/seizures, brain injury, hepatic or renal disease, diabetes, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions * Clinically significant abnormal values for urine drug screen, pulse, and blood pressure measurement (in accordance with Best Practice Guidance 13: 'Non-invasive measurement of blood pressure'). A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures * Current alcohol or substance misuse disorder * Body Mass Index under 18 and over 30 * Pregnant or planning a pregnancy, or breast feeding * Previously taken part in a study that used similar computer tasks (MRI faces task, emotional test battery) as those in the present study * Participation in a study that involves the use of a psychoactive medication or brain stimulation within the last three months * Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within last three months * Smoking \> 5 cigarettes per day, or vape a comparable amount (\> 0.5ml / a quarter of a 2ml vape); * Typically drinks \> 6 caffeinated drinks per day (e.g. tea, coffee, coca cola, Red Bull) * Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
Conditions Depression, Economic Vulnerability, Anxi...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to compare the impact of an integrated intervention combining poverty alleviation and depression treatment to depression treatment alone, in low income rural Bangladeshi women with depression. The main question\[s\] it aims to answer are whether adding poverty alleviation to depression treatment in an integrated intervention: 1) improves depression outcomes at 6 months post baseline as measured by changes in the PHQ-9 from baseline--compared to depression treatment alone; 2) reduces the chance of relapse (PHQ-9 \>=5) at 18 months among patients who remitted (PHQ-9\<5) at six months--compared to depression treatment alone; and 2) whether adding poverty alleviation to depression treatment improves implementation outcomes including treatment uptake and retention--compared to depression treatment alone. Other outcomes that will be studied include economic vulnerability and psychosocial variables such as anxiety, culturally specific symptoms, quality of life, and function. Participants in both arms will participate in research interviews at 6,12 and 18 months. The project also includes a mixed methods implementation evaluation. Quantitative implementation outcomes to be examined include adoption/uptake; retention in the intervention, and fidelity of intervention delivery. A qualitative process evaluation will include interviews with 80 study participants and approximately 40 staff members, including research staff, agricultural officers, and interventionist staff.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Manualized Group Based Psychotherapy — Participants in the control group will receive a 10-session 6-month manualized group based psychotherapy treatment. The treatment is adapted from a WHO program called Problem Management Plus (PM+). PM+ includes 4 evidence based strategies: 1) problem solving; 2) increasing social support; 3) behavioral activation; and 4) relaxation through deep breathing. The intervention is delivered by trained non professional peers.
  • Other: Poverty Alleviation — In addition to the psychotherapy intervention described above, participants in the experimental group will receive a poverty alleviation intervention adapted from the well-known Graduation Program--a poverty alleviation intervention widely used in low income countries. The poverty alleviation intervention includes a) 4 sessions of financial literacy education; b) savings accounts; c) consumption support equal to the cost of 1kg of rice per day for six months; d) productive asset transfer of 3 goats; e) 12 months of animal feed and veterinary care; f) gardening supplies; g) agricultural skill building.

Primary Outcomes

  • Change in Depressive symptoms at 6 Months (6 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: International Centre for Diarrhoeal Disease Research, Bangladesh, Georgetown University, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Alison Karasz, PhD (PRINCIPAL_INVESTIGATOR) - UMass Chan Medical School
Contact Information
Study Contact:
Alison Karasz, PhD
3478435652
alison.karasz@umassmed.edu
Fahmida Tofail, MBBS, PhD
ftofail@icddrb.org
International Centre for Diarrhoeal Disease Research
Interventions
  • Behavioral: Manualized Group Based Psychotherapy — Participants in the control group will receive a 10-session 6-month manualized group based psychotherapy treatment. The treatment is adapted from a WHO program called Problem Management Plus (PM+). PM+ includes 4 evidence based strategies: 1) problem solving; 2) increasing social support; 3) behavioral activation; and 4) relaxation through deep breathing. The intervention is delivered by trained non professional peers.
  • Other: Poverty Alleviation — In addition to the psychotherapy intervention described above, participants in the experimental group will receive a poverty alleviation intervention adapted from the well-known Graduation Program--a poverty alleviation intervention widely used in low income countries. The poverty alleviation intervention includes a) 4 sessions of financial literacy education; b) savings accounts; c) consumption support equal to the cost of 1kg of rice per day for six months; d) productive asset transfer of 3 goats; e) 12 months of animal feed and veterinary care; f) gardening supplies; g) agricultural skill building.
Study Locations (1 sites)
International Centre for Diarrhoeal Disease Research, Dhaka, Dhaka Division Bangladesh
Eligibility Criteria
Inclusion Criteria: 1. Age 18-45 2. Meets criteria for Economic Vulnerability as measured by: household income \<= 15000 Taka per month; food insufficiency in household over previous six months; OR owning \<= 10 decimals of land 3. Family willingness to participate in the program 4. Basic literacy as measured by ability to read a simple sentence; 5. A score \>=10 on the Patient Health Questionnaire (PHQ-9 Depression Scale) at baseline Exclusion Criteria: 1. Pregnancy at screen; 2. Cognitive or physical impairment precluding participation 3. Plans to relocate or to travel for \> 1 month during 18 M period. 4. Household debt greater than 70,000 Taka
Conditions Breast Cancer
Phase NA
Enrollment 854
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Our objective is based on a personalized approach of adjuvant breast radiotherapy by selecting patients according to tumor recurrence and toxicity risk.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: COHORT A — IMRT radiotherapy on whole breast according to the investigator's decision among: * Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable. * Extreme whole breast hypofractionated RT according to : * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days
  • Radiation: COHORT B — Breast radiotherapy according to the investigator's decision among: * External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed). * Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. * Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable.
  • Radiation: COHORT C — Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol: VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).
  • Radiation: COHORT D — Breast radiotherapy based on available clinical trials: \- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.

Primary Outcomes

  • Rate of patients without any grade 2 or more fibrosis, nor radio-induced sarcoma (at 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-06
Completion: 2038-03-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 854 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • AZRIA DAVID (PRINCIPAL_INVESTIGATOR) - Institut du Cancer de Montpellier - Val d'Aurelle
Contact Information
Study Contact:
MOUSSION AURORE
0467613102
aurore.moussion@icm.unicancer.fr
MOUSSION AURORE
0467613102
aurore.moussion@icm.unicancer.fr
Institut Du Cancer de Montpellier
AZRIA DAVID
Institut Du Cancer de Montpellier
Interventions
  • Radiation: COHORT A — IMRT radiotherapy on whole breast according to the investigator's decision among: * Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable. * Extreme whole breast hypofractionated RT according to : * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days
  • Radiation: COHORT B — Breast radiotherapy according to the investigator's decision among: * External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed). * Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. * Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable.
  • Radiation: COHORT C — Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol: VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions).
  • Radiation: COHORT D — Breast radiotherapy based on available clinical trials: \- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered.
Study Locations (1 sites)
Institut Du Cancer de Montpellier, Montpellier, France
Eligibility Criteria
Inclusion Criteria: General criteria (for all cohorts): 1. Women ≥ 18 years old. 2. Invasive breast cancer treated by conservative or radical surgery. 3. Conservative breast cancer surgery or radical mastectomy. 4. Indication of breast irradiation. 5. Extension evaluation of disease will be proven negative (M0). 6. Negative pregnancy test (blood or urine at the choice of investigator), to be carried out within 7 days of registration, for women of childbearing age only. 7. Effective contraception for women of childbearing age 8. Must be geographically accessible for follow-up. 9. Written and dated informed consent. 10. Affiliated to the French national social security system. Cohort A and B: \- Low risk of recurrence (all of the criteria) • pT1-T2 * SBR (Scarff Bloom et Richardson grade) grade ≤ 2 (low grade) * ER+ and / or PR+ (hormone-receptor positive) * cN0/pN- * HER 2 - * Ki67 ≤10% pN- with T3-4 and grade 3 and internal tumor will be considered at high risk of recurrence and will be proposed node irradiation (and will be switched to COHORT C or D). Cohort C and D: \- High risk of recurrence (pN+ and at least one of all) adapted from the UK PREDICT • ER- and PR- • HER2 amplified • pT3-4 • SBR grade ≥ 3 * KI67 \> 10% Cohort A and C: * Low risk of breast toxicities identified by the NovaGray RILA Breast® test Cohort B and D: \- High risk of breast toxicities identified by the NovaGray RILA Breast® test Exclusion Criteria: * 1\. Patients with distant metastases. 2\. Patients with breast DCIS (ductal carcinoma in situ) 3. Concomitant bilateral breast cancer 4. Previous breast radiotherapy 5. Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years. 6\. Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up. 7\. Patients known to be HIV positive (no specific tests are required to determine the eligibility). 8\. Patients known as hypersensitive to radiation 9. Patients treated with systemic investigational drugs during the present study (Observational cohorts are accepted if the collection of data does not interfere with the current trial) 10. Pregnant or breast-feeding women 11. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study 12. Person deprived of their liberty or under protective custody or guardianship
Conditions Hypertension, Blood Pressure, Cardiovasc...
Phase NA
Enrollment 30
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This seamless two-stage phase II/III clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. Stage 1 is a phase II, multicenter, open-label, randomized trial to determine the optimal treatment strategy. Stage 2 is a phase III, multicenter, randomized, double-blind trial investigating the efficacy and safety of optimal treatment strategy compared to sham control.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: focused power ultrasound mediate inferior perirenal adipose tissue modification — This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small "cigar"-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.
  • Device: Sham-control group — Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.

Primary Outcomes

  • Ambulatory Blood Pressure (From baseline to 1 month post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Suzhou Municipal Hospital
Collaborators: The Affiliated Jiangning Hospital of Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Affiliated Hospital of Nantong University
Contact Information
Study Contact:
Yanhui Sheng
13851647530
yhsheng@njmu.edu.cn
Yang Hua
13851624359
759150674@qq.com
Yuqing Zhang
13851672168
The Affiliated Jiangning Hospital of Nanjing Medical University
Interventions
  • Device: focused power ultrasound mediate inferior perirenal adipose tissue modification — This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small "cigar"-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.
  • Device: Sham-control group — Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Study Locations (4 sites)
The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000 China
The first Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000 China
Affiliated Hospital of Nantong University, Nantong, Jiangsu 210000 China
Suzhou Municipal Hospital, Suzhou, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: 1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and \<160 mmHg, and office diastolic blood pressure (DBP)\<100mmHg after standardized antihypertensive drug treatment for 1 month; 2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average systolic blood pressure (ASBP) ≥130 mmHg; 3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm; 4. Individual is willing to sign the informed consent of the study. Exclusion Criteria: 1. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome); 2. Individuals with ≥ 3 cardiovascular risk factors (male\>55 years old, female\>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C\<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\<50 years old; Abdominal obesity, waist circumference: male\>90cm, female\>85cm or BMI\>28kg/m2) or hypertensive target organ damage; 3. riser hypertension (defined as night blood pressure higher than daytime blood pressure by ABPM) 4. Regular night shift workers 5. Individuals taking other medications that may affect blood pressure (such as glucocorticoids); 6. Individual with history of kidney or kidney surrounding tissue surgery; 7. Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference); 8. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment; 9. Individual with type 1 diabetes or uncontrolled type 2 diabetes; 10. Individual with uncontrolled thyroid dysfunction; 11. Individual with urinary calculi or hematuria; 12. Individual with atrial fibrillation; 13. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease); 14. Individual with second degree and above atrioventricular block and/or sick sinus syndrome; 15. Individual with abnormal coagulation function; 16. Individual with infected waist skin; 17. Individual with claustrophobia; 18. Individual with malignant tumor; 19. History of allergy to amlodipine, olmesartan, and hydrochlorothiazide 20. Individual is pregnant, nursing or planning to be pregnant; 21. Individual is unwilling to sign informed consent; 22. Individual fails to complete the screening period.
Conditions Bronchopulmonary Dysplasia, Pulmonary Hy...
Phase NA
Enrollment 39
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: higher oxygen saturation target using Nellcor pulse oximetry sensors — The intervention will be a cross over exposure to the higher oxygen saturation target.
  • Device: lower oxygen saturation target using Nellcor pulse oximetry sensors — The intervention will be a cross over exposure to the lower oxygen saturation target.

Primary Outcomes

  • Intermittent hypoxemia event duration (From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-15
Completion: 2029-12-01
Eligibility
Age: 1 Month and older
Sex: ALL
Volunteers: true
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigators:
  • Samuel Gentle (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Samuel Gentle, MD
205-541-2247
samjgentle@gmail.com
Colm Travers
samuel.gentle@yale.edu
Colm Travers
205-934-4011
cptravers@uabmc.edu
The University of Alabama at Birmingham
Interventions
  • Device: higher oxygen saturation target using Nellcor pulse oximetry sensors — The intervention will be a cross over exposure to the higher oxygen saturation target.
  • Device: lower oxygen saturation target using Nellcor pulse oximetry sensors — The intervention will be a cross over exposure to the lower oxygen saturation target.
Study Locations (2 sites)
The University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Yale New Haven Hospital, New Haven, Connecticut 06510 United States
Eligibility Criteria
Inclusion Criteria: * Between 22w 0/7d and 31w 6/7d gestation at birth * Diagnosed with echocardiographic pulmonary hypertension (1) \>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg * Receiving supplemental oxygen * Have mature retinas Exclusion Criteria: * Major congenital anomalies
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Combination Product: Fecal microbial diversity — Fecal microbiome diversity via 16S rRNA and metagenomic sequencing

Primary Outcomes

  • Pathologic Complete Response (pCR) (Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-11
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pennington Biomedical Research Center
Contact Information
Study Contact:
Justin Brown, Ph.D.
225-763-3000
justin.brown@pbrc.edu
Justin Brown, Ph.D.
225-763-2715
justin.brown@pbrc.edu
Pennington Biomedical Research Center
Interventions
  • Combination Product: Fecal microbial diversity — Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
Study Locations (1 sites)
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Female biological sex * Newly diagnosed, previously untreated, histologically confirmed early triple-negative breast cancer * Plan to initiate preoperative anti-PD-1 immunotherapy using pembrolizumab * Overweight or obesity, defined as a body mass index \>=25 kg/m2 * Ability to provide written informed consent * Allow the collection and storage of biospecimens and data for future use Exclusion Criteria: * Active autoimmune disease * Concomitant conditions that require the use of antibiotics (e.g., chronic sinusitis) * Digestive disease disorders (e.g., irritable bowel syndrome, Crohn's disease) * Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks * Recent (within 90 days) use of glucocorticoids for more than 10 consecutive days * Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol * Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite advancements in Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), there remains a need for further research to replicate clinical outcomes and understand the therapeutic targets of these treatments. This study aims to address these gaps through a double-blinded, randomized, non-inferiority investigation comparing the efficacy, tolerability, cognitive adverse effects, and neurophysiological biomarkers of MST and bilateral ECT in patients with MDD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: MST — MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
  • Device: ECT — The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).

Primary Outcomes

  • the response rate (12 weeks)
  • the remission rate (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Mental Health Center
Principal Investigators:
  • TianHong Zhang, Doctor (PRINCIPAL_INVESTIGATOR) - Shanghai Mental Health Center
Contact Information
Study Contact:
TianHong Zhang, Doctor
13127577024
zhang_tianhong@126.com
TianHong Zhang, Doctor
13127577024
zhang_tianhong@126.com
Shanghai Mental Health Center
Interventions
  • Device: MST — MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
  • Device: ECT — The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
Study Locations (1 sites)
Shanghai Mental Health Center, Shanghai, Shanghai Municipality 200030 China
Eligibility Criteria
Inclusion Criteria: * Participants must meet the diagnostic criteria for MDD as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). * Participants must have a baseline score of 18 or higher on the 24-item Hamilton Depression Rating Scale (HDRS-24). * During the trial's treatment period, participants must be using a single antidepressant medication at a stable dose. * Participants must be between the ages of 18 and 65 years. * Informed consent from both parents and legal guardians is required. Exclusion Criteria: * Individuals with current or history of organic brain disorders or neurological disorders will be excluded from the study. * Participants with a Wechsler Abbreviated Scale of Intelligence (WASI) score of less than 70 will be excluded. * Individuals currently taking antiepileptic drugs, benzodiazepines, or other medications that may affect seizure activity will be excluded from the study. * Those with exposure to ECT, modified ECT, MST, transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neurostimulation treatments in last 6 months will be excluded. * Individuals with cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain will be excluded from participation. * Pregnant or lactating individuals will be excluded from the study. * Individuals currently participating in another concurrent clinical trial will not be eligible for inclusion. * Participants who refuse to provide informed consent to participate in the trial will be excluded. * Other circumstances deemed unsuitable for participation by researchers will result in exclusion.
Conditions Healthy Volunteer EGEA4 Cohort
Phase NA
Enrollment 1000
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cardiovascular (CV) diseases affect 523 million people worldwide, and are the leading cause of death, accounting for over 18 million deaths (around 30% of all deaths) every year. CV diseases account for around 45% of all deaths in Europe, or around 140,000 deaths a year in France. Asthma is one of the main non-communicable diseases, with a significant societal and individual burden, particularly in subjects suffering from severe asthma. The prevalence of asthma worldwide has risen rapidly over the past five decades, and now affects 272 million people worldwide, representing a prevalence of around 3.6%. Asthma is often associated with multimorbidity. Allergic rhinitis, chronic sinusitis, sleep apnea syndrome, gastro-oesophageal reflux disease, obesity and hormonal disorders are among the most common conditions associated with asthma. More recently, other chronic conditions linked to asthma have been suggested, including CV diseases. Although data from the literature in recent years suggest that asthma is associated with an increased risk of major CV events, the underlying mechanisms remain poorly understood. In particular, it is not known whether asthma and CV disease share common etiological processes, such as anthropometric parameters, lifestyle, social, environmental and/or genetic factors, or whether CV disease is a direct consequence of certain features of asthma, such as systemic inflammation or asthma treatments. Our study is based on the hypothesis that the risk of CV events is increased in patients with asthma, which is supported by a growing body of scientific data.However, it remains to be determined to what extent this increased risk is a consequence of asthma or is linked to shared risk factors between asthma and CV health. We hypothesize that asthma, and more specifically adult and moderate-to-severe asthma, are associated with early markers of CV risk. Furthermore, by providing a better understanding of the mechanisms involved in this association, we hypothesize that EGEA\_30years may help to disentangle and prioritize actionable levers of life-threatening cardiovascular comorbidities in asthma.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: blood test, food collection, hair collection, calcium scan, etc. — everything is specified during the phone call and in the consent form to be signed

Primary Outcomes

  • Framingham score variability between asthmatics and non-asthmatics (during clinical examination)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-15
Completion: 2028-02-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Collaborators: APHP, Hospices Civils de Lyon, APHM, University Hospital, Grenoble, University Hospital, Montpellier
Principal Investigators:
  • Valérie Siroux, PHD (PRINCIPAL_INVESTIGATOR) - Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Valérie Siroux, PHD
0476549451
valerie.siroux@univ-grenoble-alpes.fr
Bruno DEGANO, PhD
BDEGANO@chu-grenoble.fr
Centre Hospitalier Universitaire Grenoble Alpes
Gilles Mr DEVOUASSOUX, MD
gilles.devouassoux@chu-lyon.fr
Hopital de la Croix Rousse
Interventions
  • Other: blood test, food collection, hair collection, calcium scan, etc. — everything is specified during the phone call and in the consent form to be signed
Study Locations (5 sites)
Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, 38043 France
Hopital de la Croix Rousse, Lyon, 69317 France
APHM, Marseille, 13000 France
Hôpital Arnaud De Villeneuve, Montpellier, 34295 France
APHP - Hôpital Bichat Claude Bernard, Paris, 75018 France
Eligibility Criteria
Inclusion Criteria: * Have participated in at least one of the previous EGEA surveys; * to be affiliated to a social security scheme or to be a beneficiary of such a scheme. Exclusion Criteria: * Person deprived of liberty by judicial or administrative decision; * Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship).
Conditions Type2diabetes, Heart Failure With Preser...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria make more short chain fatty acids, a byproduct the team thinks may benefit participant's health.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Potato Starch — Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption. In addition, participants will have evaluations and provide blood and stool samples during the study.

Primary Outcomes

  • Changes in Short Chain Fatty Acid (SCFA) butyrate levels - stool (Baseline, approximately 4 weeks)
  • Changes in Short Chain Fatty Acid (SCFA) butyrate levels - plasma (Baseline, approximately 4 weeks)
  • Changes in propionate levels - stool (Baseline, approximately 4 weeks)
  • Changes in propionate levels- plasma (Baseline, approximately 4 weeks)
  • Changes in acetate levels- stool (Baseline, approximately 4 weeks)
  • Changes in acetate levels- plasma (Baseline, approximately 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Principal Investigators:
  • Scott Hummel, MD, MS (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Hayley Billingsley, PhD
734-726-0308
hbilings@med.umich.edu
Hayley Billingsley, PhD
734-726-0308
hbilings@med.umich.edu
University of Michigan
Scott Hummel, MD, MS
University of Michigan
Interventions
  • Dietary Supplement: Potato Starch — Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption. In addition, participants will have evaluations and provide blood and stool samples during the study.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * A confirmed clinical diagnosis of stable HFpEF on maximally tolerated Heart Failure (HF) medical regimen (without changes in dosage in the prior month) * Left ventricular ejection fraction of \>50% documented in the prior 12 months * A confirmed clinical diagnosis of Type II diabetes (T2DM) with glycated hemoglobin \<10% without changes in medical regimen in the past month. Exclusion Criteria: * Current usage of pre- or probiotic usage * Antibiotic usage in the past 6 months * Current participation in another interventional clinical trial * History of potato allergy or potato starch allergy, inflammatory bowel syndrome, inflammatory bowel disease, bowel resection, Roux-en-Y gastric bypass surgery, celiac disease, Crohn's disease, or colorectal cancer * Hypoglycemic episode with blood glucose 70 milligrams per deciliter (mg/dL) within the last month * Stage IV-V chronic kidney disease * Pregnancy (self-reported) * Comorbidity limiting survival to \< 12 months